Michael Szarek, PhD, on Treatment Advances With Tivozanib for RCC Going Forward

Video

The expert from SUNY Downstate Medical Center highlighted areas in which he believes treatment for renal cell carcinoma will advance.

In an interview with CancerNetwork®, Michael Szarek, PhD, of the SUNY Downstate Medical Center, spoke about where he believes renal cell carcinoma treatment will advance in the coming years.

Transcription:

Tivozanib [Fotivda] is a [tyrosine kinase inhibitor]. There are a lot of different drugs that are approved for renal cell carcinoma. One of the future [prospects] is obviously for the PD-1 class to move into renal cell carcinoma more and more. Combinations with PD-1 [inhibitors] is one area. Hopefully, if tivozanib is approved, then I think other sponsors and perhaps the sponsor of the drug itself will look into combining it with other agents including [PD-1 inhibitors]. So that’s one likely future avenue for the treatment of renal cell carcinoma.

Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Related Content